Subtype
Esophageal and Gastroesophageal Junction Carcinoma
CI-CAN-00002608Explore in graph →
460 active trials11 approved drugs34 evidence items
- NCIt
- C203673
Loading cancer entity…
Subtype
CI-CAN-00002608Explore in graph →
Clinical trials
1,309 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (120)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | recruiting | Phase 2 / Phase 3 | 224 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07529808 | Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 164 | BigHat Biosciences, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07603375 | Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma(TNT Esophagus) | recruiting | Phase 2 | 60 | Duke UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07392892 | Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | recruiting | Phase 2 / Phase 3 | 840 | PfizerINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07733180 | A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC | recruiting | Phase 2 | 30 | BeOne MedicinesINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06005493 | Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 392 | AstraZenecaINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | recruiting | Phase 1 / Phase 2 | 134 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06123338 | A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer | recruiting | Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06253650 | Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease(TRINITY) | recruiting | Phase 2 | 46 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06329869 | Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma(SG-ESCC) | recruiting | Phase 2 | 35 | National Taiwan University HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06780111 | Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) | recruiting | Phase 1 / Phase 2 | 298 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Sep 17, 2026 | clinicaltrials |
| NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | recruiting | Phase 1 / Phase 2 | 205 | Terremoto Biosciences Inc.INDUSTRY | 4 | Sep 17, 2026 | clinicaltrials |
| NCT07405151 | A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) | recruiting | Phase 1 / Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Sep 17, 2026 | clinicaltrials |
| NCT06324357 | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | recruiting | Phase 1 / Phase 2 | 768 | Boehringer IngelheimINDUSTRY | 10 | Sep 16, 2026 | clinicaltrials |
| NCT07751341 | A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 84 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06730373 | First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) | recruiting | Phase 2 | 110 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06732388 | Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus | recruiting | Phase 2 | 76 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07818018 | A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07000253 | Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma(OMEC-5) | recruiting | Phase 2 | 290 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 3 | Sep 10, 2026 | clinicaltrials |
| NCT07811752 | Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer | recruiting | Phase 2 | 28 | Shanghai Chest HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07282912 | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels(OLIGOMETS) | recruiting | Phase 2 | 54 | Yale UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | recruiting | Phase 1 / Phase 2 | 230 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 2, 2026 | clinicaltrials |
| NCT07795749 | Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) | recruiting | Phase 2 | 55 | University of California, IrvineOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07796113 | Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC | recruiting | Phase 2 | 24 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07700667 | SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 120 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787273 | Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 84 | Hefei Cancer Hospital of the Chinese Academy of SciencesNETWORK | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07594626 | BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion | recruiting | Phase 1 / Phase 2 | 72 | Northwestern UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07001748 | Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity(STOPGAP II) | recruiting | Phase 2 / Phase 3 | 148 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07222657 | Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma | recruiting | Phase 2 | 40 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04939051 | Obeticholic Acid for Prevention in Barrett's Esophagus | recruiting | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07751055 | Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer(NEOCRTE2601) | recruiting | Phase 2 | 51 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07699939 | Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma(PLATANUS) | recruiting | Phase 2 | 136 | National Cancer Center, JapanOTHER_GOV | 2 | Aug 5, 2026 | clinicaltrials |
| NCT05705492 | Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer | recruiting | Phase 2 | 66 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07464756 | SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer | recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07554456 | A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) | recruiting | Phase 2 / Phase 3 | 90 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04840264 | Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction | recruiting | Phase 2 | 79 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07699185 | Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 336 | Tongji HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07689851 | Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer | recruiting | Phase 2 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07403136 | Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC | recruiting | Phase 2 | 104 | Fudan UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06747585 | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | Alentis Therapeutics AGINDUSTRY | 8 | Jun 29, 2026 | clinicaltrials |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | recruiting | Phase 2 | 72 | Dan ZandbergOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06038578 | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | recruiting | Phase 2 | 146 | Toray Industries, IncINDUSTRY | 3 | Jun 23, 2026 | clinicaltrials |
| NCT07339488 | Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma(ILDR-03) | recruiting | Phase 2 | 43 | Chuangzhen ChenOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07655024 | TAIC FOLFOX for Locally Advanced G/GEJA(TFLAG) | recruiting | Phase 2 | 31 | Guang'anmen Hospital of China Academy of Chinese Medical SciencesOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07638436 | Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma(NEOCRTEC2501) | recruiting | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
Data updated just nowSource updated Sep 29, 2026source: clinicaltrials